MINI LONG - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 17:38:09 14/05/2024 BST | ||
| 22.69 EUR | -1.94% |
|
| Current month | +13.65% | ||
| 1 month | +12.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
| Date | Price | Change |
|---|---|---|
| 14/05/24 | 22.69 | -1.94% |
| 13/05/24 | 23.14 | +2.75% |
| 10/05/24 | 22.52 | +0.49% |
| 09/05/24 | 22.41 | -0.84% |
| 08/05/24 | 22.6 | +3.62% |
Delayed Quote Deutsche Boerse AG
Last update May 14, 2024 at 05:38 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | CP61X4 |
| ISIN | DE000CP61X40 |
| Date issued | 01/03/2019 |
| Strike | 178.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.36 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.26 € |
|---|---|
| Lowest since issue | 2.49 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
429.9
USD
Average target price
462.6
USD
Spread / Average Target
+7.59%
- Stock Market
- Certificates
- Certificat
